Shuttle Pharmaceuticals Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $4.79M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Feb 17, 2026 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 22, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 15, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 26, 2023 | Before market open | – | – | – |
Press releases
Announcements Shuttle Pharmaceuticals filed with the SEC
Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Merges with United Dogecoin to Become the World’s Largest Public Dogecoin Miner
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Announces $3.5 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Other events · EX-99.1 to Form 8-K
SHUTTLE PHARMA FILES PROVISIONAL PATENT FOR PSMA LIGAND CONJUGATES TO TREAT PROSTATE CANCER
Other events · EX-99.1 to Form 8-K
Pharma Announces Pricing of $5.75 Million Underwritten Offering
Material agreement · Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Announces Closing of $5.75 Million Underwritten Offering
Material agreement · Listing notice · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Executive or director change · Other events · EX-99.1 to Form 8-K
Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Other events · EX-99.1 to Form 8-K
Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Listing notice · Other events · EX-99.1 to Form 8-K
Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Provides Third Quarter 2024 Corporate Update
Results of operations · EX-99.1 to Form 8-K
Shuttle Pharmaceuticals Holdings, Inc. Announces
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Present at the 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Pharma Provides Second Quarter 2024 Corporate Update
Other events · EX-99.1 to Form 8-K
Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Pharma Ready to Enroll patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma Appoints Timothy Lorber as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Provides First Quarter 2024 Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May
Other events · EX-99.1 to Form 8-K
Pharma Provides Fourth Quarter 2023 Corporate Update
Results of operations · EX-99.1 to Form 8-K
Emerging Growth Conference on March 6, 2024
Listing notice · Other events · EX-99.1 to Form 8-K
Pharma Announces Its Intent to Pursue a Rights Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Provides Third Quarter 2023 Corporate Update
Results of operations · EX-99.1 to Form 8-K
Shuttle Pharma Advances Prostate Cancer Predictive
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
Other events · EX-99.1 to Form 8-K